Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Aquestive Therapeutics, Inc. (AQST)
Last aquestive therapeutics, inc. earnings: 3/11 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.aquestive.com/investor-relations
Company Research
Source: GlobeNewswire
Met all endpoints in Phase 3 pivotal study for Anaphylm™ (epinephrine) Sublingual Film in first quarter 2024 when compared to EpiPen® and other injectors used for the treatment of anaphylaxisOn track to complete Anaphylm temperature/pH study in second quarter 2024Received positive feedback from FDA on Anaphylm self-administration and allergen exposure protocols; remains on track to complete both studies in third quarter 2024Continues to target filing an Anaphylm New Drug Application (NDA) with the FDA by the end of 2024Received FDA approval and U.S. market access for Libervant™ (diazepam) Buccal Film in patients between ages two to fiveExtended cash runway into 2026 with completion of $77.5 million underwritten public offering with high quality institutional healthcare investorsTo host investment community conference call at 8:00 am ET on May 8, 2024 WARREN, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medic
Show less
Read more
Impact Snapshot
Event Time:
AQST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AQST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AQST alerts
High impacting Aquestive Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AQST
News
- Global Oral Transmucosal Drugs Market Size To Exceed USD 62.3 Billion By 2033 | CAGR Of 6.5% [Yahoo! Finance]Yahoo! Finance
- Aquestive Therapeutics, Inc. (NASDAQ: AQST) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- Aquestive Therapeutics, Inc. (NASDAQ: AQST) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $8.00 price target on the stock.MarketBeat
- Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year [Yahoo! Finance]Yahoo! Finance
AQST
Earnings
- 5/7/24 - Miss
AQST
Sec Filings
- 5/13/24 - Form 4
- 5/13/24 - Form 4
- 5/8/24 - Form 8-K
- AQST's page on the SEC website